
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| ELYXYB | Scilex Pharmaceuticals | N-212157 RX | 2020-05-05 | 1 products, RLD, RS |
| CELEBREX | Upjohn | N-020998 RX | 1998-12-31 | 4 products, RLD |
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| CONSENSI | Purple Biotech | N-210045 DISCN | 2018-05-31 | 3 products, RLD |
Brand Name | Status | Last Update |
|---|---|---|
| celebrex | New Drug Application | 2024-11-22 |
| celecoxib | ANDA | 2025-11-17 |
| celecoxib 100 mg | ANDA | 2015-11-30 |
| celecoxib 200 mg | ANDA | 2019-11-01 |
| celecoxib 400 mg | ANDA | 2015-11-27 |
| celecoxib 50 mg | ANDA | 2015-11-28 |
| celecoxib celecoxib | ANDA | 2021-12-21 |
| elyxyb | New Drug Application | 2020-05-13 |
| elyxyb - celecoxib | New Drug Application | 2024-11-26 |
| generic drug | ANDA | 2022-01-17 |
Expiration | Code | ||
|---|---|---|---|
CELECOXIB / TRAMADOL HYDROCHLORIDE, SEGLENTIS, KOWA PHARMS | |||
| 2024-10-15 | NP | ||
CELECOXIB, ELYXYB, SCILEX HLDG | |||
| 2023-05-05 | NP | ||
Patent | Expires | Flag | FDA Information |
|---|---|---|---|
| Amlodipine Besylate / Celecoxib, Consensi, Purple Biotech | |||
| 10350171 | 2038-06-14 | DP | |
| 10925835 | 2038-06-14 | U-2410 | |
| 10945960 | 2038-06-14 | DP | |
| 9408837 | 2030-02-28 | U-2410 | |
| 9662315 | 2029-05-22 | DP | U-2410 |
| Celecoxib, Elyxyb, Scilex Hldg | |||
| 9572819 | 2036-05-27 | DP | U-2718 |
| 9795620 | 2036-05-27 | DP | U-2718 |
| 9949990 | 2036-05-27 | DP | U-2718 |
| 10376527 | 2036-05-27 | DP | U-2718 |
| 10722456 | 2036-05-27 | DP | U-2718 |
| 10799517 | 2036-05-27 | DP | U-2718 |
| Celecoxib / Tramadol Hydrochloride, Seglentis, Kowa Pharms | |||
| 8846744 | 2031-06-03 | DP | |
| 8598152 | 2030-04-19 | DS, DP | |
| 9012440 | 2030-04-19 | DS, DP | |
| 10238668 | 2030-04-19 | DS, DP | U-3244 |
| 10245276 | 2030-04-19 | DS, DP | |
| 10548909 | 2030-04-19 | U-3244 | |
| 11478488 | 2030-04-19 | U-3244 | |

Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Knee osteoarthritis | D020370 | EFO_0004616 | M17 | — | 1 | 1 | — | — | 2 |
| Hip osteoarthritis | D015207 | EFO_1000786 | M16 | — | 1 | 1 | — | — | 2 |
| Drug common name | Celecoxib |
| INN | celecoxib |
| Description | Celecoxib is a member of the class of pyrazoles that is 1H-pyrazole which is substituted at positions 1, 3 and 5 by 4-sulfamoylphenyl, trifluoromethyl and p-tolyl groups, respectively. A cyclooxygenase-2 inhibitor, it is used in the treatment of arthritis. It has a role as a cyclooxygenase 2 inhibitor, a geroprotector, a non-steroidal anti-inflammatory drug and a non-narcotic analgesic. It is a member of toluenes, a sulfonamide, a member of pyrazoles and an organofluorine compound. |
| Classification | Small molecule |
| Drug class | cyclooxygenase-2 inhibitors |
| Image (chem structure or protein) | ![]() |
| Structure (InChI/SMILES or Protein Sequence) | Cc1ccc(-c2cc(C(F)(F)F)nn2-c2ccc(S(N)(=O)=O)cc2)cc1 |
| PDB | — |
| CAS-ID | 169590-42-5 |
| RxCUI | — |
| ChEMBL ID | CHEMBL118 |
| ChEBI ID | 41423 |
| PubChem CID | 2662 |
| DrugBank | DB00482 |
| UNII ID | JCX84Q7J1L (ChemIDplus, GSRS) |












